trending Market Intelligence /marketintelligence/en/news-insights/trending/KomskNs5Hw_nlCIwfHG88Q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Bioblast Pharma regains compliance with Nasdaq listing rule

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bioblast Pharma regains compliance with Nasdaq listing rule

Bioblast Pharma Ltd. regained compliance with a Nasdaq listing rule that requires the company to maintain a minimum bid price of $1 per share.

After 10 consecutive business days following the company's 1-for-5 reverse stock split on Sept. 25, the closing bid price for Bioblast's ordinary shares was $1 per share or greater, the company said in a filing.